← Back to Futures
mid utopian B 4.39

The Orphan Question Cooperative

By 2034, families affected by rare diseases use autonomous research systems to form cooperatives that commission microtrials, turning the selection of questions and the consent process into patient-owned institutions.

Turning Point: The turning point arrives when a national drug regulator approves the first adaptive trial sponsored by a patient cooperative, after its elected trustees sign the protocol and a partner hospital accepts shared clinical liability.

Why It Starts

Research systems make plausible hypotheses abundant, but deciding which uncertainty deserves a patient's limited time remains irreducibly human. Families pool records, money, and lived experience to govern small trials that commercial sponsors overlook. By publishing failures as well as successes, their cooperatives gradually turn neglected diseases into a patient-directed research commons.

How It Branches

  1. Autonomous systems cross-read trial registries, molecular data, and patient diaries to identify testable mechanisms for diseases too small to attract commercial portfolios.
  2. Families pool consented records and membership dues in disease-specific cooperatives, then elect trustees to rank research questions.
  3. Hospitals run small adaptive protocols only after trustees and designated clinicians verify the endpoints and accept defined responsibilities.
  4. Publishing failed treatment arms prevents duplication, while promising findings advance to larger, publicly funded trials.

What People Feel

At 6:40 p.m. in a borrowed hospital classroom in Manchester, Daniel raises a red card to halt a proposed trial involving his daughter's condition. Twelve families wait as he asks whether the researchers are choosing an easier measurement simply because the outcome that truly matters is harder to prove.

The Other Side

Wealthier, better-connected families can build stronger cooperatives, leaving less visible diseases behind. Trustees may also become too emotionally invested to reject an elegant hypothesis that exposes members to even marginal risk.